Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Each year, over two million people fall victim to snakebites, resulting in more than 100,000 fatalities and 300,000 severe ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29.

Genmab (NASDAQ:GMAB), a biotechnology company with a market capitalization of $16.91 billion specializing in cancer ...

"This is probably the coolest experimental result I've had in my career so far," said biochemist Susana Vázquez Torres.

According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...

Dara Khosrowshahi, CEO of Uber, championed the role of AI in transforming the physical world at the conference. He proclaimed that the future of transportation is "electric, autonomous, and shared." ...

Collaboration Marks First At-Scale Deployment of AI Technologies into Leading Commercial BiobankBOSTON and HUNTSVILLE, Ala, Jan. 23, 2025, a leading biospecimens and specialty lab testing company, to ...

ImmunoPrecise Antibodies (IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

In this interview, Technology Networks spoke with Dr. Sophie Mayle, Dr. Paul Royle and Dr. John Cardone from Bio-Rad's ...